New freezing biopsy could make lung cancer diagnosis safer
NCT ID NCT04548830
First seen Jun 25, 2026 · Last updated Jul 02, 2026 · Updated 3 times
Summary
This study tests whether a biopsy technique called transbronchial cryobiopsy is safer than the standard method for diagnosing lung cancer. About 100 adults with known or suspected lung cancer will undergo the procedure under general anesthesia. Researchers will track complications to see if this freezing-based approach reduces risks.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- transbronchial cryobiopsy (a procedure using a freezing probe to take lung tissue samples)
- What this could lead to
- If successful, this could offer a safer and more effective way to diagnose lung cancer, reducing complications from standard biopsies.
- What could go wrong
- This is a small, early-phase study focused on safety, not treatment. The procedure may still carry risks like bleeding or lung collapse, and results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
115 people
The number who actually took part.
- Started
-
Sep 2020
- Finished
-
Jun 2026
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * 18 years of age or greater * Patients with known or suspected diagnosis of cancer and indeterminant pulmonary nodules or diffuse parenchymal lung disease with non-diagnostic clinical profiles for whom a lung biopsy is deemed useful for diagnosis. Exclusion Criteria: * Patients with pulse oximetry less than 92% on oxygen delivery up to 2 L nasal cannula. * Uncorrectable coagulopathy defined as: * Platelet count \<50,000 x 10\^9/L or * prothrombin time international normalized ratio \>1.5 * Known pulmonary hypertension or echocardiographic pulmonary artery systolic pressure \>50mmHg * A secure diagnosis based on clinical and high-resolution CT scan data. * Antiplatelet therapy that cannot be held for more than 5 days. * Any patient deemed unfit to undergo bronchoscopy by the proceduralist * Female patients with a positive pregnancy test within 30 days of the planned study procedure
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Lung cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Memorial Sloan Kettering Cancer Center (All Protocol Activities)
New York, New York, 10065, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Surgeons could freeze lung tumors from miles away using 5G robots
- Can AI make lung cancer scans easier to read?
- Two-Drug combo targets Treatment-Resistant lung cancer
- Can an Anti-Fibrotic drug shield lungs from radiation after immunotherapy?
- App aims to catch a hidden radiotherapy side effect
- Which nerve block wins for lung surgery pain?